| 15.18 -1.125 (-6.9%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.68 | 1-year : | 24.16 |
| Resists | First : | 17.7 | Second : | 20.68 |
| Pivot price | 14.51  |
|||
| Supports | First : | 14.45 | Second : | 12.44 |
| MAs | MA(5) : | 15.93 |
MA(20) : | 14.77 |
| MA(100) : | 11.37 |
MA(250) : | 29.77 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 79.7 |
D(3) : | 84.1 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 100.09 | Low : | 6.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JBIO ] has closed below upper band by 36.1%. Bollinger Bands are 57.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.17 - 16.25 | 16.25 - 16.33 |
| Low: | 14.55 - 14.65 | 14.65 - 14.74 |
| Close: | 15.02 - 15.18 | 15.18 - 15.32 |
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Wed, 21 Jan 2026
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock - MSN
Mon, 19 Jan 2026
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue - Yahoo Finance
Sun, 18 Jan 2026
Short Interest in Jade Biosciences, Inc. (NASDAQ:JBIO) Increases By 47.9% - MarketBeat
Sat, 17 Jan 2026
Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wed, 07 Jan 2026
HC Wainwright & Co. Initiates Coverage of Jade Biosciences (JBIO) with Buy Recommendation - Nasdaq
Tue, 06 Jan 2026
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 79.3 (%) |
| Shares Short | 1,550 (K) |
| Shares Short P.Month | 1,170 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 2.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.55 |
| Dividend | 2.4 |
| Forward Dividend | 0 |
| Dividend Yield | 15.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|